Aside from issuing its final report (which we don’t discuss in detail here owing to its similarity to that discussed in our earlier coverage, above),
This was the question directed to state regulators from the chair of the Natural Medicine Advisory Board’s (“NMAB”) combined subcommittee, Dr. Bradley Conner, during the
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture. Subscribe AnnuallySubscribe Monthly Already
Longstaff: It seems a case then with standards, particularly when it comes to the individual researchers and those backing them, they have to show a
Gosh, it’s been a busy few weeks! Our news cycle has been dominated by Lykos Therapeutics-related stories, from ICER’s report and panel meeting through to FDA’s
While obtaining a patent on the drug itself might be tricky—Merck had patented MDMA over a hundred years ago in 1912 after it found it
Current Rules Status: Proposed. Public comment: Written comments may be submitted through this form. Oral comments permitted during rulemaking hearings. Final rulemaking hearing: July 25th,
Instead, now that the dust has begun to settle, I (Josh Hardman) attempt to explore some of the lesser-discussed themes that emerged in the meeting,
Live Coverage: FDA Advisory Committee Reviews MDMA-Assisted Therapy for PTSDJune 4, 2024 Follow our live coverage of the FDA’s Psychopharmacologic Drugs Advisory Committee meeting to
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture. Subscribe AnnuallySubscribe Monthly Already